Adenocard Articles
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
8 December 2009
S-P begins enrollment for heart bypass trial
20 May 2009
Can-Fite initiates Ph I/II trial of liver cancer drug
20 April 2009
Biogen's PD drug passes Ph II testing
27 March 2009
Pharma/biotech mergers and acquisitions in 2008
12 January 2009
King Pharma files CorVue NDA with FDA
12 January 2009
Duska and DSM in manufacturing accord
17 November 2008
FDA clears Akorn's ANDA for adenosine inj
10 November 2008
CV Thera initiates CVT-3619 trial
8 September 2008
Biogen Idec initiates Ph III trial of Adentri
1 September 2008
King's profit drops 34% in 2nd-qtr 2008 to $43M
18 August 2008
Clinical Data buys Adenosine Thera
18 August 2008
Duska files Ph III ATPace protocol with FDA
4 August 2008
Japan stock market week to June 30, 2008
7 July 2008
Lexiscan launch earns CV $10M milestone
30 June 2008
Japan stock market week to Aril 21, 2008
28 April 2008
FDA approval for CV and Astellas' Lexiscan
28 April 2008
Sagent launches generic cefazolin injection
24 March 2008
FASgen reveals potential stroke therapy data
24 December 2007
EU funded scientists decode proteins with medicines potential
5 November 2007
Cardium's Generx gets FDA fast track
30 July 2007
Merck & Co to buy NovaCardia for $350M
30 July 2007
S-P licenses ARA drug from PeriCor
30 July 2007
CORvalen improves symptoms of CFS
20 November 2006
Kinex selects oncology drug for clinical development
12 September 2005
CV Thera's asthma drug candidate enters Ph I
25 July 2005
FDA OK's Xsira's IND for IV adenosine
18 July 2005
Duska Thera licenses P2R glaucoma IP
27 June 2005
Xanthus' Xanafide sees good safety data
30 May 2005
Fujisawa's 9-month sales rise 2.5%
21 February 2005
Aspirations of Astellas Pharma, the merged Yamanouchi/Fujisawa
22 November 2004
Almirall and Neurocrine in PD deal
15 November 2004
Daiichi sees first-half revenues fall 2%
15 November 2004
Tokyo pharma stocks - week to October 25
1 November 2004
Lilly's CS-747 shows good safety profile
13 September 2004
Vernalis leaps 104% on $400M Frova deal
26 July 2004
Can-Fite starts US Ph I trial of CF101
19 July 2004
Stock Commentary - Europe
5 July 2004
Fujisawa updates status of pipeline
8 March 2004
Promising Ph II data for Biogen's Adentri
17 November 2003
ICN to start Ph III studies for Viramidine
17 November 2003
CV Thera initiates Ph III of CVT-3146
3 November 2003
Tokyo pharma stocks - week to Oct 13
20 October 2003
Vernalis regains control of its A2A antagonists
16 June 2003
Fujisawa drug clears Phase II for AF
31 March 2003
Fujisawa's tacrolimus in Phase III for IBD
11 March 2002
Kyowa says Parkinson's drug trials are promising
25 February 2002
Vernalis unveils new Parkinson's disease drug
14 January 2002
Fujisawa sales soar in North America
12 November 2001
CVT begins Ph II angina trial for CVT-3146
30 August 2001
Japan pharma stocks in week to August 27
29 August 2001
CV Therapeutics begins Ph II CVT-3146 trial
23 August 2001
King Pharmaceuticals 2nd-qtr earnings leap 77%
25 July 2001
CV Therapeutics' second drug enters Phase III
3 July 2001
Biogen CHF results boost new candidate
21 March 2001
Vivus licenses MED drug from Tanabe
8 March 2001
CV Therapeutics raises $120 million
9 August 2000
Viagra safe for stable heart disease patients
2 June 2000
CVT enters pivotal studies with CVT-510
18 May 2000
ATP infusion of benefit in cancer patients
25 February 2000
Biogen and CVT, Phase II promise with CHF compound
18 February 2000
CV Therapeutics soars on ranolazine data
23 August 1999
Hyseq's CD39-L4: potential in MI?
14 July 1999
CVT starts Phase II trial of antiarrhythmic
25 June 1999
Suntory files adenosine in Japan
26 May 1999
Enzon - improving the delivery and side effect profile of proven
20 January 1999
CV Therapeutics - An Overlooked Opportunity
17 December 1998
Aventis Pipeline Rich In Near-Term Prospects
10 December 1998
Fujisawa Reports Steady Interim Growth
11 November 1998
R-PR Drops Klerval From Development
16 October 1998
Fujisawa Fights Back In Shrinking Domestic Market
15 September 1998
CV Therapeutics, Ph II CVT-124 Data
4 June 1998
Fujisawa Restructuring In The USA, Revises Forecasts
31 March 1998
Cypros Expands Adenosine Portfolio
13 February 1998
Round-Up Of Products Entering Clinical Trials
27 January 1998
Product License News In Brief
20 November 1997
Adenosine + Thrombolysis Cuts Infarcts
18 November 1997
88% Increase In EPS For 3rd Qtr At Medco
15 October 1997
Cortex, Enzon And Mylan Results
11 September 1997
Adenoscan In Japan
26 June 1997
CV Therapeutics And Biogen Begin CVT-124 Phase II
21 April 1997
Antisense For Asthma From Epigenesis
3 March 1997
Gensia Initiates Phase I GP3269 Trial
1 July 1996
US Corporate Results Round-Up
27 May 1996
Adenosine A1 Receptor Blocker Clears Ph I
25 March 1996
Medco's ATP Improves Cancer Prognosis
8 January 1996
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
